Pro-inflammatory dietary patterns and their association with cardiovascular disease and pancreatic cancer in a hospital population: a cross-sectional study.
단면연구
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
24 participants (6.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] In this pragmatic clinical setting, a brief, food-based inflammatory diet score did not discriminate cross-sectional differences in pancreatic-cancer prevalence or CVD, nor did it correlate meaningfully with hsCRP. These null findings bound plausible effect sizes and support the need for larger, prospective studies with richer dietary phenotyping and biomarker integration.
[OBJECTIVE] To examine whether a concise, clinic-feasible Patient Inflammatory Diet Score (PIDS) relates to prevalent pancreatic cancer and cardiovascular disease (CVD) in a hospital population, and t
- 95% CI 0.32-2.06
- 연구 설계 cross-sectional
APA
Jin Q, Liu Y, et al. (2025). Pro-inflammatory dietary patterns and their association with cardiovascular disease and pancreatic cancer in a hospital population: a cross-sectional study.. Frontiers in nutrition, 12, 1666682. https://doi.org/10.3389/fnut.2025.1666682
MLA
Jin Q, et al.. "Pro-inflammatory dietary patterns and their association with cardiovascular disease and pancreatic cancer in a hospital population: a cross-sectional study.." Frontiers in nutrition, vol. 12, 2025, pp. 1666682.
PMID
41648754 ↗
Abstract 한글 요약
[OBJECTIVE] To examine whether a concise, clinic-feasible Patient Inflammatory Diet Score (PIDS) relates to prevalent pancreatic cancer and cardiovascular disease (CVD) in a hospital population, and to explore associations with systemic inflammation.
[METHODS] We conducted a cross-sectional study among 401 adults (≥40 years) attending cardiology, gastroenterology, or oncology services (2018-2022). A 10-12-min questionnaire captured sociodemographics, lifestyle, and habitual intake of pro- and anti-inflammatory food groups to derive the PIDS (quartiles). Pancreatic cancer and CVD were ascertained from de-identified electronic records; high-sensitivity C-reactive protein (hsCRP) indexed systemic inflammation. Robust Poisson models estimated prevalence ratios (PRs) across PIDS quartiles with prespecified adjustments and subgroup/sensitivity analyses.
[RESULTS] Pancreatic cancer was present in 24 participants (6.0%); CVD in 111 (27.7%). Relative to Q1, fully adjusted PRs for pancreatic cancer were 0.81 (95% CI 0.32-2.06), 0.94 (0.39-2.27), and 1.09 (0.45-2.65) for Q2-Q4 (p-trend = 0.79); the per-SD estimate was 1.03 (0.81-1.31). PIDS showed no material association with prevalent CVD (Q4 vs. Q1, PR 1.08; 0.76-1.54; p-trend = 0.61). Correlation with hsCRP was weak ( = 0.09; = 0.08), and findings were consistent across sex, age, and BMI strata, alternative PIDS categorizations, exclusion of hsCRP > 10 mg·L, and restriction to participants without CVD. No synergistic effects were observed for joint PIDS-CVD categories.
[CONCLUSION] In this pragmatic clinical setting, a brief, food-based inflammatory diet score did not discriminate cross-sectional differences in pancreatic-cancer prevalence or CVD, nor did it correlate meaningfully with hsCRP. These null findings bound plausible effect sizes and support the need for larger, prospective studies with richer dietary phenotyping and biomarker integration.
[METHODS] We conducted a cross-sectional study among 401 adults (≥40 years) attending cardiology, gastroenterology, or oncology services (2018-2022). A 10-12-min questionnaire captured sociodemographics, lifestyle, and habitual intake of pro- and anti-inflammatory food groups to derive the PIDS (quartiles). Pancreatic cancer and CVD were ascertained from de-identified electronic records; high-sensitivity C-reactive protein (hsCRP) indexed systemic inflammation. Robust Poisson models estimated prevalence ratios (PRs) across PIDS quartiles with prespecified adjustments and subgroup/sensitivity analyses.
[RESULTS] Pancreatic cancer was present in 24 participants (6.0%); CVD in 111 (27.7%). Relative to Q1, fully adjusted PRs for pancreatic cancer were 0.81 (95% CI 0.32-2.06), 0.94 (0.39-2.27), and 1.09 (0.45-2.65) for Q2-Q4 (p-trend = 0.79); the per-SD estimate was 1.03 (0.81-1.31). PIDS showed no material association with prevalent CVD (Q4 vs. Q1, PR 1.08; 0.76-1.54; p-trend = 0.61). Correlation with hsCRP was weak ( = 0.09; = 0.08), and findings were consistent across sex, age, and BMI strata, alternative PIDS categorizations, exclusion of hsCRP > 10 mg·L, and restriction to participants without CVD. No synergistic effects were observed for joint PIDS-CVD categories.
[CONCLUSION] In this pragmatic clinical setting, a brief, food-based inflammatory diet score did not discriminate cross-sectional differences in pancreatic-cancer prevalence or CVD, nor did it correlate meaningfully with hsCRP. These null findings bound plausible effect sizes and support the need for larger, prospective studies with richer dietary phenotyping and biomarker integration.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Synchronous Retrograde Replantation Method for the Repair of Completely Severed Toes: A Four-Year Follow-Up.
- Neoadjuvant Chemotherapy Can Effectively Avoid Unnecessary Extended Resection for Gastric Cancer with Clinical Evidence of Duodenum or Pancreas Head Involvement.
- New Strategies in Comprehensive Melanoma Treatment: Applications, Potential, and Challenges of Hydrogels.
- Global landscape of early-onset thyroid cancer: current burden, temporal trend and future projections on the basis of GLOBOCAN 2022.
- Deep learning and multi-omics reveal programmed cell death-associated diagnostic signatures and prognostic biomarkers in gastric cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Key Considerations for Targeting in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.
- The role of disulfidptosis-driven tumor microenvironment remodeling in pancreatic cancer progression.
- Current Systemic Treatment Options for Advanced Pancreatic Cancer-An Overview Article.
- Editorial: Altered metabolic traits in gastro-intestinal tract cancers, volume II.
- Racial Disparities in Pancreatic Cancer: A Comprehensive Population-Based Analysis of Survival, Surgical Access, and Prognostic Factors.
- Impact of Skeletal Muscle-related Parameters on Survival in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine plus Nab-paclitaxel as First-line Chemotherapy.